See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report for: Benitech Biopharma
SYDNEY, April 25, 2016 /PRNewswire/ — Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or ‘expressed RNAi’, today announced acceptance of five presentations at the 19th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT) being held in Washington D.C. on May 4-7, 2016. The abstracts cover the scientific results from three of Benitec’s programs: hepatitis B, OPMD and hepatitis C, with the key findings briefly summarised below.
David Suhy, Chief Scientific Officer of Benitec Biopharma, stated: “This meeting is one of the most important international meetings on gene and cell therapy. To have five abstracts accepted demonstrates the interest and importance in the work that Benitec is doing across its programs and will give our research further exposure to a global audience. As we move ahead with our programs, we will update both the scientific and investor communities on our clinical priorities and next phases of development.”
1. Oral Presentation: BB-HB-331, a DNA-Directed RNA Interference (ddRNAi) Agent Targeting Hepatitis B Virus (HBV), Can Effectively Suppress HBV In Vitro and In Vivo
Presenter: David Suhy, PhD
In vitro treatment of PXB-derived primary human hepatocytes with Ad-BB-HB-331 led to significant decreases in HBV parameters with dose dependent expression of the anti-HBV shRNAs and corresponding inhibition of the HBV viral RNAs.
Similarly, effective suppression of HBV infection was observed following in vivo treatment of PXB mice with AAV8-BB-HB-331.
Through the first 28 days of an ongoing 56-day experiment, treatment with the high dose resulted in decreases in extracellular levels of HBsAg and HBeAg by 90% and 84%, respectively, when compared to the untreated control. In addition, treatment with the same dose resulted in nearly a log reduction of extracellular HBV DNA at 28 days.
In a press release dated March 8, 2016, Benitec reported the data from the full 56-day in vivo study which demonstrated a further marked improvement over the results above. Dr Suhy will present the full data set at the conference.
2. Oral Presentation: Gene Therapy Rescues Disease Phenotype in the Oculopharyngeal Muscular Dystrophy Mouse Model
Presenter: David Suhy, PhD (on behalf of Professor George Dickson)
Treating mice affected by OPMD over 4 months with an AAV gene therapy strategy based on DNA-directed RNA interference to silence the endogenous expPABPN1, combined with the re-expression of a healthy sequence-optimized human PABPN1 gene, significantly reduces the amount of nuclear aggregates in affected muscles, decreased the intramuscular fibrosis and reverted the muscle strength to the level of healthy wild-type muscles.
Although muscle atrophy was not reverted, the expression of a healthy PABPN1 markedly increased the cross sectional area of muscle fibres.
3. Oral Presentation: Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV)
Presenter: David Suhy, PhD
The three doses of TT-034 administered to date have been well tolerated in human subjects infected with the hepatitis C virus (HCV) and there have been no reported serious adverse events related to administration of the study drug.
The initial dose (4E10 vg/kg) resulted in very low levels of transduction as expected.
The second dose (1.25E11 vg/kg) resulted in the detection of substantially higher levels of TT-034 in hepatocytes, the predominant cell type in the liver, yielding 0.48, 3.65 and 10.44 copies of TT-034 DNA per cell in the three patients, respectively.
The first subject administered with the third dose (4.00E11 vg/kg) had 17.74 copies of TT-034 per cell, indicating that a significant portion of their hepatocytes may have been transduced, and expression of anti-HCV shRNAs was clearly detected in the transduced hepatocytes.
4. Poster: Durable Expression of TT-034 in Cynomolgus Monkey Hepatic and Cardiac Tissues without Long-Term Adverse Effects on Endogenous MicroRNA Levels
Presenter: David Suhy, PhD
A single, intravenous infusion of TT-034 results in almost complete transduction of Cynomolgus monkey hepatocytes and results in durable expression of three anti-HCV shRNAs.
The doses of TT-034, meant to encompass the range of doses administered in a human clinical study, do not cause long-term perturbation of endogenous miRNA levels.
5. Poster: A Comparison of scAAV8-TT-034 Mediated Transduction and shRNA Expression in Human Liver Biopsy Samples versus a Chimeric Mouse Model with Humanized Liver
Presenter: David Suhy, PhD
Residual mouse hepatocytes present in the chimeric livers are transduced more efficiently with the scAAV8 vector than human hepatocytes resulting in lower overall transduction and shRNA expression as compared to similar data obtained from the TT-034 human clinical samples.
While these models can serve as a surrogate to assess the activity of gene therapy constructs against functions of normal human liver, the doses required for optimal activity may be modestly higher than required in the human clinical setting.
The full abstracts have been published on the conference website and can be accessed at the following link: http://www.abstractsonline.com/pp8/#!/4077. A copy of the oral presentations and posters will be accessible on May 4, 2016 by visiting the Investor sections of www.benitec.com and selecting News/Resources and Presentation
Source – Company Press Release
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.
Stock market
Hot small cap stocks
small cap stock picks
Biotech stocks
FDA approval stocks
FDA calendar
Trade stocks
Become a day trader
Day trade stocks for a living
PDUFA date set
micro cap stocks
Best stocks 2016
Hottest small cap stocks
Best stock picks
Who to follow for stock picks
Apple news stock picks
Stock picks on apple news
